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Abstract
Background: Genomic instability with frequent DNA copy number alterations is one of the key hallmarks of carcinogenesis.
The chromosomal regions with frequent DNA copy number gain and loss in human gastric cancer are still poorly defined. It
remains unknown how the DNA copy number variations contributes to the changes of gene expression profiles, especially
on the global level.
Principal Findings: We analyzed DNA copy number alterations in 64 human gastric cancer samples and 8 gastric cancer cell
lines using bacterial artificial chromosome (BAC) arrays based comparative genomic hybridization (aCGH). Statistical analysis
was applied to correlate previously published gene expression data obtained from cDNA microarrays with corresponding
DNA copy number variation data to identify candidate oncogenes and tumor suppressor genes. We found that gastric
cancer samples showed recurrent DNA copy number variations, including gains at 5p, 8q, 20p, 20q, and losses at 4q, 9p,
18q, 21q. The most frequent regions of amplification were 20q12 (7/72), 20q12–20q13.1 (12/72), 20q13.1–20q13.2 (11/72)
and 20q13.2–20q13.3 (6/72). The most frequent deleted region was 9p21 (8/72). Correlating gene expression array data with
aCGH identified 321 candidate oncogenes, which were overexpressed and showed frequent DNA copy number gains; and
12 candidate tumor suppressor genes which were down-regulated and showed frequent DNA copy number losses in
human gastric cancers. Three networks of significantly expressed genes in gastric cancer samples were identified by
ingenuity pathway analysis.
Conclusions: This study provides insight into DNA copy number variations and their contribution to altered gene
expression profiles during human gastric cancer development. It provides novel candidate driver oncogenes or tumor
suppressor genes for human gastric cancer, useful pathway maps for the future understanding of the molecular
pathogenesis of this malignancy, and the construction of new therapeutic targets.
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Introduction
Gastric cancer is one of the most common malignancies and the
second most common cause of cancer related death worldwide [1].
The major type of gastric cancer is adenocarcinoma, which can be
further categorized into intestinal type and diffuse type [2].
Intestinal-type lesions are frequently ulcerative and occur in the
distal stomach. Diffuse-type lesions are associated with a worse
prognosis than the intestinal type. Surgical treatment is the only
therapeutic modality that has a potentially curative effect to gastric
cancer. The prognosis of gastric cancer patients depends heavily
on the clinical and pathological stage of the disease at diagnosis.
The 5-year survival rates after curative surgical resection decline
from 60–90% in stage I to only 10–25% for patients in stage III of
the disease [3]. Most gastric cancer patients are identified at the
advanced stage, which leads to the dismal prognosis.
Genetic alterations are key events in the development of most
tumors, including gastric cancer [4]. Studies suggest that tumor
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somal aberrations leading to gains or losses of part of the tumor
cell genome. Therefore, characterization of genomic abnormal-
ities may help elucidate the molecular pathogenesis of gastric
cancer as well as reveal the genetic markers of progression.
Array-based comparative genomic hybridization (aCGH) is a
powerful method used to identify pathogenic DNA copy number
changes on a genome-wide scale [5]. aCGH has been applied to
a number of solid tumors, including gastric cancer [6,7]. It has
been shown to be useful in the identification of novel oncogenes
and tumor suppressor genes, and to classify tumors based on
genetic changes.
Expression profiling experiments identified a large numbers of
genes which are differentially expressed in normal and tumor
tissues. However, most of these genes are likely to be passenger
genes which have limited contribution to tumorigenesis. The key
challenge has been to identify driver oncogenes or tumor
suppressor genes that play important roles during tumor initiation
and progression, Genomic DNA copy number variation is an
important type of genetic alteration observed in tumor cells, and it
contributes to tumor evolution by alterations of the expression of
genes within the region [8]. DNA copy number gains and losses
are not random, but rather represent consistent genetic events
during carcinogenesis. Identification of genes that are both over-
expressed and amplified or under-expressed and deleted may be
beneficial because these genes may represent driver genetic
alterations.
Previous studies have reported DNA copy number changes or
expression profiles in gastric cancer samples. The studies have also
identified common chromosome gains and losses, as well as
hundreds of genes that may distinguish tumors from normal tissues
[6,9]. However, few studies have investigated the association
between DNA copy number variations and transcriptional
expression profiles. In this manuscript, we performed aCGH
analysis in a large number of human gastric cancer samples.
Furthermore, integrated analysis of DNA copy number variations
andcorrespondinggene expressionvalueswas performed toidentify
significant genes that may contribute to gastric cancer pathophys-
iology. A total of 321 candidate oncogenes and 12 candidate tumor
suppressor genes were identified through the analysis.
Materials and Methods
Ethic Statement
The use of archival gastric specimen for the current study was
approved by the Ethics Committee of the University of Hong
Kong and the Internal Review Boards of University of California,
San Francisco.
Tumor Samples, Cell Lines and DNA, RNA Preparation
Tumor samples were collected from gastrectomy specimens
from the Department of Surgery, Queen Mary Hospital, The
University of Hong Kong. Eight gastric cancer cell lines AGS,
BGC823, N87, NUGC3, SNU16, SNU5, KATOIII and MNK45
have been described in our previous publications [10]. Genomic
DNA was extracted using the Genomic DNA purification Kit
(Qiagen, Valencia, CA).
The clinico-pathological parameters of the tumors have been
previously published [11]. Tumors were classified using Lauren’s
classification of intestinal, diffuse, mixed, and indeterminate types
[2]. The presence of H. pylori in the gastrectomy specimens was
determined by histological examination and supplemented by
modified Giemsa staining. The presence of EBV in cancer cells
was assayed by in situ hybridization for EBER as previously
described [12]. The tumor stages were defined by the General
Rules for Gastric Cancer Study of the Japanese Research Society
for Gastric Cancer [13].
Array-based CGH
Human 1.14 arrays were obtained from the UCSF Cancer
Center Array Core (http://cc.ucsf.edu/microarray/). They
consisted of 2353 bacterial artificial chromosome (BAC) clones
that covered the human genome at 1.5 Mb resolution. For
hybridization, 1 mg of tumor DNA and 1 mg of gender matched
reference DNA was labeled by random priming using Cy3-dCTP
and Cy5-dCTP, respectively, with the Bioprime Kit (Invitrogen).
Unincorporated fluorescent nucleotides were removed using a
Sephadex G-50 column (Amersham, Piscataway, NJ). Sample
and reference DNA were mixed with 100 mg Cot-1, precipitated,
and resuspended in hybridization solution. The hybridization
solution was denatured for 10 min at 72uC and then incubated
for 1 h at 37uC. Hybridization was performed for 48–72 hrs in a
moist chamber on a slow rocking table. Arrays were washed for
10 min in 50% formamide and 26SSC at 45uC, and 10 min in
phosphate buffer at room temperature. Slides were mounted in
mounting solutions containing 0.3 mg/ml DAPI. Three single-
color intensity images (DAPI, Cy3 and Cy5) were collected for
each array using a charge coupled device camera.
Array-based CGH Data Analysis
The UCSF SPOT software [14] was used to automatically
segment the spots based on the DAPI images, perform local
background corrections, and calculate various measurement
parameters including log2 ratios of the total integrated Cy3 and
Cy5 intensities for each spot. Raw data of the aCGH are available
at GEO (accession number: GSE33501).
Program SPROC was used to associate clone identities and a
mapping information file with each spot so that the data could be
plotted relative to the position of the BACs. Chromosomal
aberrations were classified as a gain when the normalized log2
Cy3/Cy5 ratio was .0.225 and as a loss when the ratio was
,20.225. The number was determined as 3-fold the average SD
of normal versus normal aCGH hybridization. Amplifications
were identified when the normalized log2 Cy3/Cy5 ratio was
.0.8. Similarly, homozygous deletions were identified when the
normalized log2 Cy3/Cy5 ratio was ,20.7. Multiple gains, losses,
and amplifications were counted as separate events. The threshold
of gain or loss of an entire chromosome arm was defined as the
median log2 ratio of .0.225 or ,20.225 for all clones on the
chromosome arm.
Statistical Data Analysis
Samples were categorized based on the experimental results
and compared with the clinical data (Table S1) using significant
analysis of microarray (SAM) analysis [15]. DNA copy number
alterations including median percentage of gain and loss.
Frequent amplification and deletion were analyzed by using
CGH explorer 3.2 (http://www.ifi.uio.no/forskning/grupper/
bioinf/Papers/CGH/). ‘‘Analysis of Copy Errors’’ (ACE) was
performed using a false discovery rate (FDR) of 0.0001 and
medium sensitivity. Clustering of all samples was performed in
TreeView version 1.60.
R/Bioconductor software, including the CBS program, was
used to compute the correlation between copy number change
and gene expression. The expression data of the 6688 cDNA
clones used in the previous gene expression analysis [11,16] (GEO
accession number: GSE2701) was retrieved. Mapping position for
these cDNA clones were assigned using the NCBI genome
DNA CNVs and Gene Expression Analysis in GCs
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(NCBI build 35). The aCGH data was segmented using circular
binary segmentation (CBS) as implemented in the DNA copy
package in R/Bioconductor to translate experimental intensity
measurements into regions of equal copy numbers. Missing values
for clones mapping within segmented regions of equal copy
numbers were imputed by using the value of the corresponding
segment. The gene expression clones were mapped to the BAC
clone within 1 Mb of the gene expression clone which had the
highest Pearson correlation between copy number and gene
expression. ‘‘Smoothed’’ values from CBS with the originally
observed log2 ratio for the outlier clones described above and the
imputed values for missing values were considered in computing
correlation with gene expression. Correlation was only computed
for clones, and a correlation coefficient of 0.29 was used as the
cut-off to identify clones having positive correlation between copy
number and gene expression. p-values for the gene expression and
copy number correlations were obtained based on permutation.
The labels of expression data were randomly shuffled and the
Pearson correlation between gene expression clones and copy
number BAC clones were calculated as described previously. This
was repeated 1000 times. For each gene expression clone, the p-
value was determined as the proportion of times the permutation
based correlation was greater than or equal to the observed
correlation. The p-values were then corrected for multiple testings
by controlling for the false discover rate (FDR) using the
Benjamini-Hochberg method [17].
Functional analysis of the significant genes was performed using
Ingenuity Pathway software (Ingenuity Systems, Redwood City,
CA).
Results
Array-based CGH Analysis of Human Gastric Cancer
To identify DNA copy number alterations in gastric cancers, we
applied BAC aCGH to 64 human gastric cancer tissue samples
and 8 gastric cancer cell lines. The raw data are available in Table
S2. We observed recurrent chromosomal variations in these
samples, and regions with significant DNA copy number changes
were identified. The resulting frequency plot and aberration plot
of gains and losses are shown in Figure 1A and Figure 1B
respectively. Two representative genome-wide ratio plots for
individual gastric tumor are shown in Figure S1. The most
common DNA copy number variations in this set of human gastric
tumors as determined by the median percentage of gain or loss
included gains of 5p, 8q, 20p, 20q, and losses of 4q, 9p, 18q, 21q.
Next,weanalyzedDNAcopynumbervariationsingastriccancer
samples with different clinico-pathological features including tumor
stage, tumor type, tumor site, tumor differentiation, Helicobacter
pylori and EBV infection, as well as the difference between gastric
tumor samples and cell lines, (Figure S2, S3, S4, S5, S6, S7, S8 and
Table S3). We found specific chromosomal aberrations enriched in
certain clinico-pathological features. For example, loss of 19p was
more frequently observed in stage 1 & stage 2 tumors (20%) than in
stage 3 & stage 4 samples (3.41%) (Table S3). 16p loss was identified
in 10% of the Helicobacter pylori negative samples compared with
0% in the Helicobacter positive samples, while 16p gain was
observed in 14.71% of the Helicobacter pylori positive samples but
only in 3.33% of the Helicobacter negative samples (Table S3).
These results suggest the possible contribution of genes within
specific regions to specific tumor phenotypes.
High-level amplifications and homozygous deletions are sum-
marized in Table S4. The most frequent amplification was found
at the long arm of chromosome 20. In this region, four separate
focal amplicons could be identified: 20q12 (7/72), 20q12–20q13.1
(12/72), 20q13.1–20q13.2 (11/72) and 20q13.2–20q13.3 (6/72).
The second most frequent amplification, occurring in the long arm
of chromosome 8, also had four separate focal amplicons: 8q23.1
(3/72), 8q24.1 (7/72), 8q24.12–8q24.2 (6/72) and 8q24.2 (6/72).
The most frequent homozygous deletion region was found at 9p21
(8/72) and at 18q22 (6/72). Other high-level amplifications and
homozygous deletions occurred at relatively lower frequencies.
Examples of frequent aberrations are shown in Figure 2. Some
well-characterized oncogenes (e.g., HER2, TOP2A, CyclinE, TGFB1,
AKT2, MYC) and tumor suppressor genes (e.g., P16, SMAD4,
SMAD7) are found to be located in these loci. Interestingly, a higher
number of amplifications and homozygous deletions were identified
in the cell lines than in the primary gastric cancer tumor samples.
Contribution of Genomic DNA Copy Number Variation to
Global Gene Expression Changes in Human Gastric
Cancer Samples
In our previous study, we reported the gene expression profile in
90 primary gastric cancer samples compared with their 14
Figure 1. DNA copy number alterations by aCGH. (A) Overall
frequency of DNA copy number alterations by aCGH. Frequency
analysis measured as a fraction of cases gained or lost over all the BAC
clones on the arrays. Data presented was ordered by chromosomal map
position of the clones. Lower bars represented losses and upper bars
represented gains. The purple vertical bars represented the boundary
between each chromosome. (B) DNA copy number alterations in each
gastric cancer samples. 72 tumor samples were ordered from top to
bottom. Red columns represented copy number gains and green
columns represented copy number losses.
doi:10.1371/journal.pone.0029824.g001
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with 6688 cDNA clones showing significant variation across these
samples [11,16]. Among the 90 gastric cancer samples, 62
specimens were included in the current aCGH study. In order
to determine whether genomic DNA copy number variations
contribute to global gene expression pattern changes, we
determined the correlation between gene expression values and
the corresponding DNA copy number changes in these 62 human
gastric cancer samples on a gene by gene basis. Of the 6688 cDNA
in the original expression studies, 5719 cDNA clones with position
information were retrieved for this analysis. Of these 5719 cDNA
clones, 1352 cDNA clones (23.6% of the total cDNA clones
analyzed), representing approximately 973 unique genes, showed
statistical significant correlation between expression values and
DNA copy number variations (correlation .0.29 and adjusted p
value less than 0.01 with FDR less than 3.4%. See Table S5 for the
list of genes). To illustrate whether DNA copy numbers influence
gene expression, we compared the pair wise correlation of gene
expression data with either aCGH values of BAC clones close to the
locus where each gene is located at (diagonal), or aCGH values of
BAC clones located at other regions of the genome. We found pairs
of regions along the diagonal have higher positive correlation
(median correlation ,0.12) than the off-diagonal pairs (median
correlation ,0.0) (Figure S9A). A heatmap of the pairwise corre-
lation between gene expression and copy number also demonstrates
the positive correlation along the diagonal (Figure S9B).
Overall, our data confirm that genomic DNA copy number
variations contribute to the regulation of regional gene expression
profiles in human gastric cancer samples.
Identification of Candidate Oncogene or Tumor
Suppressor Genes for Human Gastric Cancers
To pinpoint candidate oncogenes or tumor suppressor genes,
we applied two criteria to the list of 1352 cDNA clones which
showed statistically significant correlation between gene expression
and corresponding DNA copy number changes. First, we searched
for genes that showed 5 more gains than losses or 5 more losses
than gains in gastric cancer samples. Next, we matched the gene
list with the 3329 cDNA clones that were identified to be
differentially expressed between non-tumor gastric tissues and
human gastric cancer samples [11]. Thus, we narrowed our list to
363 clones, representing 333 unique genes (Table S6). Among
these genes, 321 genes were up-regulated in gastric cancer samples
and were frequently gained or amplified at the genomic DNA
level. The remaining 12 genes were down-regulated in gastric
cancer samples and were frequently deleted at the genomic DNA
level. These two set of genes, therefore, represent potential
candidate oncogenes or tumor suppressor genes, respectively,
which may be involved in gastric cancer pathogenesis and
development.
DNA Copy Number Changes with the Corresponding
Gene Expression Values in Selected Gene Clusters in
Human Gastric Cancers
To further illustrate how DNA copy number variations
influence gene expression, we analyzed the expression patterns
of the 333 candidate oncogenes and tumor suppressor genes in the
62 gastric cancer samples using hierarchical clustering (Figure 3A).
No associations were identified between the clustering pattern and
clinical features (Figure S10), suggesting that these genes do not
provide additional values for molecular classification of human
gastric cancer. Interestingly, several gene clusters were found to be
located at the same chromosomal regions, including genes located
at 6p21.3–p21.1, 7q21–q22, 8q21–q24, 8q24.3, 12q14–q15,
20q11–q13 and 20q13.3 (Figure 3B to 3H). An overall strong
correlation between coordinated upregulated expression of these
gene clusters and DNA copy number gains in the corresponding
chromosomal regions was observed (Figure 3B to 3H). It suggests
that DNA copy number variation is a key contributor to the
expression variation of these genes within the cluster.
Pathway Analysis of Significantly Expressed Genes
The Ingenuity Pathway Analysis (IPA) software was employed
to investigate the interactions among the candidate oncogenes or
tumor suppressor genes identified by expression array and aCGH.
Figure 4 shows the three most significant networks of interaction in
gastric cancer samples. Network 1 was specifically associated with
cancer, renal & urological disease, and cell cycle. Network 2 was
specifically associated with connective tissue development and
function, cancer, and gastrointestinal disease. Network 3 was
specifically associated with genetic disorder, skeletal & muscular
disorders, and inflammatory disease (Table S7). All networks
reached a score of 21 or higher and contained 11 or more genes,
which demonstrated the extensive relationship and interaction
among the significantly regulated genes in gastric cancer. Top
biological functions of these genes were related to cell cycle, DNA
replication, recombination and repair, energy production, and
nucleic acid metabolism (Figure S11). All these functions are
known to be involved in tumorigenesis, providing possible links
between the identified candidate oncogenes and tumor suppressor
genes during gastric cancer development.
Discussion
Gene copy number alterations are particularly important as
deregulating events in cancer progression. In this study, we
analyzed Copy Number Aberrations (CNAs) by array CGH.
Frequent gains and losses were identified from the study.
Furthermore, chromosomal regions with high levels of amplifica-
tions and homozygous deletions were also described. Additionally,
correlation between gene expression and DNA CNAs were
investigated. Candidate oncogenes and tumor suppressor genes
were identified by performing integrated analyses of genome copy
number and gene expression. Finally, relationships among these
candidate genes and their biological function were described in 3
networks using the Ingenuity pathway analysis. The data support
that combining aCGH and gene expression array analysis is a
powerful method to identify candidate oncogenes or tumor
suppressor genes in human gastric cancer. Consistent with this
paper, previous studies have applied similar approaches to identify
driver genetic events in other tumor types, such as liver cancer
[18] and breast cancer [19]. Interestingly, more candidate
oncogenes were identified than candidate tumor suppressor genes
Figure 2. DNA copy number analysis of representative amplicons and homozygous deletions. Clones were ordered by their position
from pter (left) to qter (right). The log2 ratios of every clone in these specific cases were plotted as broken line graphs with different color. Multiple
clear copy number changes (gains, losses, amplifications and deletions) can be recognized. The center of amplicon and homozygous deletion cores
were indicated together with genes in each core region. (A) Amplification in 17q11.2–17q21. (B) Amplification in 19q12–19q13.1. (C) Amplification in
8q24.1–8q24.2. (D) Homozygous deletion in 18q21.1. (E) Homozygous deletion in 9p21. (F) Homozygous deletion in 16q23. (G) Homozygous
deletion in 18q12.
doi:10.1371/journal.pone.0029824.g002
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magnitude range of gain compared to loss in tumor samples
combined with compressed ratios from admixed non-tumor cells.
The difference in gene numbers may also suggest that the
expression of oncogenes may be more profoundly regulated by
CNAs than tumor suppressor genes are.
Figure 3. Hierarchical clustering of gastric tumors. (A) Hierarchical clustering the patterns of variation in expression of 333 candidate
oncogene and tumor suppressor genes (from Table S6) in 62 gastric tumors. Each row represented a separate cDNA clone on the microarray and
each column represented the expression pattern in a separate tumor or tissue sample. The ratio of abundance of transcripts of each gene to its mean
abundance across all tissue samples was depicted according to the color scale shown at the bottom. Gray indicated missing or excluded data. The
dendrogram at the top of the figure represented the hierarchical clustering of the tumors based on similarity in their pattern of expression of these
genes. (B) to (H) compared DNA copy number changes with the corresponding gene expression values in selected gene clusters in each individual
tumor sample. See Table S8 for full data.
doi:10.1371/journal.pone.0029824.g003
Figure 4. Ingenuity networks in gastric cancer samples. Ingenuity networks generated by mapping the candidate oncogenes and tumor
suppressor genes identified by integrated analysis of expression array and aCGH data. Each network was graphically displayed with genes or gene
products as nodes (different shapes represented the functional classes of the gene products) and the biological relationships between the nodes as
edges (lines). The length of an edge reflected the evidence in the literature supporting that node-to-node relationship. The intensity of the node color
indicated the degree of up- (red) or downregulation (green) of the respective gene. Genes in uncolored notes were not identified as differentially
expressed in our experiment and were integrated into the computationally generated networks on the basis of the evidence stored in the IPA
knowledge memory indicating a relevance to this network. A solid line without arrow indicated protein-protein interaction. Arrows indicated the
direction of action (either with or without binding) of one gene to another.
doi:10.1371/journal.pone.0029824.g004
DNA CNVs and Gene Expression Analysis in GCs
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e29824In the aCGH analysis, frequent gains and amplifications were
detected in gastric cancer samples. Of note, consistent with
previous studies [20,21], 20q was the most frequent site of gain
detected in gastric cancer samples. Amplification at 20q has also
been reported in several other cancers, such as breast cancer [22]
and pancreatic cancer [23]. In our study, high level amplifications
were found at 20q12–q13.3 in gastric cancer. Several genes are
located at this locus, such as AIB1 and BCAS1. AIB1 (20q12), a
steroid receptor co-activator first found amplified in breast and
ovarian cancer, is involved in gastric cancer cell proliferation
through interaction with nuclear receptors [24]. BCAS1 (20q13.2),
breast carcinoma amplified sequence 1, is amplified in a variety of
tumor types and is associated with more aggressive tumor
phenotypes. Up-regulated expression of BCAS1 is significantly
correlated with the high level amplification of 20q13 in
adenocarcinomas of the gastro-esophageal junction [25]. 8q was
the second most frequent site of gain as it was detected in 26.39%
of the samples. Amplification at 8q has been identified in many
cancers, such as breast cancer and pancreatic cancer [23,26]. In
our study, high level amplifications were found at 8q24.1–q24.2 in
gastric cancer. Several genes are located at this locus. MYC is the
most representative one. It is one of the most studied oncogenes,
which contributes to the malignancy of many different aggressive
and undifferentiated human cancers [27]. The pathologic effect of
MYC has been ascribed to its ability to control multiplecellular
processes such as cell growth, differentiation, apoptosis, DNA
damage response, genomic instability, angiogenesis, and tumor
invasiveness [28].
Another important high level amplification was found at
17q12–q21. The representative genes located at this locus is
ERBB2. Overexpression and/or amplification has been observed
in many kinds of cancers, including gastric cancer [29,30,31].
Correlation between ERBB2 amplification and overexpression is
noted by comparing aCGH and expression array data in our
gastric cancer data set (Figure S12). Overexpression and
amplifications were identified in only a small number (,6 of 72)
of gastric cancer samples. This may explain why ERBB2 was not
selected in the correlated candidate oncogene list as it did not pass
the criteria as one of the differentially expressed genes.
Nevertheless, the result clearly suggests that amplification of
17q12–q21 may represent a key mechanism for high levels of
ERBB2 expression in a subset of human gastric cancer samples.
Gastric cancer patients with 17q12–q21 amplification may benefit
from treatment with Herceptin, a humanized antibody, designed
to target and block the function of ERBB2.
Consistent with the study by Gorringe KL, et al, amplifications at
6p21 and 5p13 were also identified in our array CGH results [7].
It is intriguing to note that a disproportionally higher numbers of
high-level amplifications and homozygous deletions were identi-
fied in gastric cancer cell lines compared to tissue samples. The
observation indicates that these amplifications or deletions may
provide growth advantages during in vitro cell culture, and
therefore are enriched in cell lines. The results highlight the
importance of these high-level amplifications and homozygous
deletions in regulating cell proliferation or survival. The cell lines
with these amplifications or deletions provide excellent resources
to help further study the functional roles of the genes within these
regions during gastric cancer development.
Previous studies have provided insights into the importance of
specific copy number alterations in the development of epithelial
tumors, showing that these alterations may lead to the altered
expression of critical oncogenes or tumor suppressors [21,31,32].
Our study therefore confirms these previous reports and provides
evidence to support that CNA represents an important factor in
regulating the abnormal up or down-expression of these genes
during gastric cancer carcinogenesis. However, most of the genes
identified from our studies are still likely to be passenger genes
whose expression are highly gene-dose dependent, and have
limited functional roles during tumorigenesis. Since these CNVs
are not random and the main consequence of CNVs in tumors
cells is likely to be the de-regulation of the expression of genes
important for tumorigenesis, driver oncogenes and tumor
suppressor genes are likely to be included in the large number of
genes that we have identified. Clearly, further functional analysis is
required to identify these driver oncogenes and tumor suppressor
gene among our genelist. To achieve this goal, one can apply a
siRNA based screen to silence the expression of candidate
oncogenes in gastric cancer cell lines. Similar studies have been
performed using breast cancer cell lines. Such functional screens
prove to be critical to narrow down the true driver oncogenes. For
example, Thollet A et al showed that siRNA-mediated silencing of
ZNF217 expression in MCF7 breast cancer cells led to decreased
cell proliferation and increased sensitivity to paclitaxel [33].
Overall, our studies provide a list of candidate genes that need
to be further investigated functionally. Nevertheless, the genelist
already provides some interesting genes as candidate oncogenes
whose oncogenic potential has been demonstrated in other tumor
types. The genes include NOTCH1 [34,35,36], BMI1
[37,38,39,40,41], EFNA1 [42,43], NCOA2 [44], BYSL [45,46],
and RAD21 [47]. For example, Notch1, a member of Notch family
receptor has been indicated as an oncogene in multiple tumor
types. High expression of NOTCH1 was observed in human breast
cancer and colorectal cancer, both of which are correlated with
poor outcome of cancer patients [34]. Activated NOTCH1 induced
lung adenomas in mice and cooperated with Myc in the
generation of lung adenocarcinoma [35]. Recent studies showed
that the Notch1 receptor intracellular domain (N1IC), the
activated form of Notch1 receptor, was associated with gastric
cancer progression through cyclooxygenase-2 [36]. Therefore,
Notch signaling pathway may be a new target for treatment of
gastric cancer. A second example is Bmi1. BMI1, B-cell-specific
Moloney murine leukemia virus insertion site 1, is a member of a
polycomb group of transcriptional repressors and was originally
identified as an oncogene associated with c-myc in the develop-
ment of murine lymphoma [37]. Additional work has revealed that
BMI1 had been associated with tumor development and
progression. For example, BMI1 alone has been shown to induce
malignant transformation of HaCaT cells [38]. Up-regulation of
BMI1 can promote cell proliferation and prevent apoptosis [39].
Moreover, BMI1 is related to proliferation, survival, and poor
prognosis in pancreatic cancer [40]. Recently, high expression of
BMI1 was observed both in gastric cancer cell lines and gastric
tumors. Overexpression of BMI1 was found to be correlated with
advanced clinical stage and lymph node metastasis in gastric
cancer patients [41]. Taking it all together, BMI1 may become a
new biomarker in supporting the diagnosis and determining the
prognosis of gastric cancer in clinical practice though more studies
still should be done.
Our study also identified several candidate tumor suppressor
genes. IQGAP2 is such a candidate. Several studies have already
suggested the tumor suppressing activity of IQGAP2. For
example, it was showed that IQGAP2 deficiency results in an
86% incidence of hepatocellular carcinoma in IQGAP2 knockout
mouse model [48]. IQGAP2 expression is downregulated in more
invasive and metastatic liver cancer cell lines as well as most
human hepatocellular carcinoma tissue [49]. Additionally,
IQGAP2 inactivation by hypermethylation is found in human
gastric cancer samples [50] and IQGAP2 knockdown with siRNA
DNA CNVs and Gene Expression Analysis in GCs
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Our study showed that down-regulation of IQGAP2 is also
regulated by DNA copy number loss. The discovery of both
genetic and epigenetic mechanisms for repressing IQGAP2
expression in gastric cancer provides strong evidence in support
of IQGAP2 acting as a tumor suppressor gene and calls for further
investigation on the role of IQGAP2 in gastric tumor develop-
ment.
Supporting Information
Figure S1 Two representative genome-wide ratio plots
for individual gastric tumor. Log2 ratio for each of the
genomic clones was plotted according to chromosome position. (A)
Whole genome DNA copy number profile of gastric cancer tissue
sample HKG24T. Note that this sample showed the following
DNA copy number variations: +3q, +5p, +8q, +13q, +17p, 24q,
210p and 218q. (B) Whole genome DNA copy number profile of
gastric cancer cell line N87. Note that this sample showed the
following DNA copy number variations: +5p, +8q, +11q, +20q,
23p, 25q, 26p, 26q, 27q, 28p, 211p, 214q, 217p and 221q.
In addition, it also has amplification at 8q21, 8q24, 11q22 and
17q21.
(PDF)
Figure S2 DNA copy number variations in gastric
cancer samples with different tumor differentiation.
Data presented are ordered by chromosomal map position of the
clones. Lower green bars represent losses or deletions, and the
upper red bars represent gains or amplifications. (A) Well &
moderate differentiated tumor. (B) Poor differentiated tumor.
(PDF)
Figure S3 DNA copy number variations in gastric
cancer samples with different tumor site. Data presented
are ordered by chromosomal map position of the clones. Lower
green bars represent losses or deletions, and the upper red bars
represent gains or amplifications. (A) Tumor site: antrum. (B)
Tumor site: body. (C) Tumor site: cardia.
(PDF)
Figure S4 DNA copy number variations in gastric
cancer samples with different tumor stage. Data presented
are ordered by chromosomal map position of the clones. Lower
green bars represent losses or deletions, and the upper red bars
represent gains or amplifications. (A) Stage 1 & 2 tumor. (B) Stage
3 & 4 tumor.
(PDF)
Figure S5 DNA copy number variations in gastric
cancer samples with different tumor type. Data presented
are ordered by chromosomal map position of the clones. Lower
green bars represent losses or deletions, and the upper red bars
represent gains or amplifications. (A) Tumor type: diffuse type. (B)
Tumor type: intestinal type.
(PDF)
Figure S6 DNA copy number variations in gastric
cancer tumors or cell lines. Data presented are ordered by
chromosomal map position of the clones. Lower green bars
represent losses or deletions, and the upper red bars represent
gains or amplifications. (A) Tissue samples. (B) Cell lines.
(PDF)
Figure S7 DNA copy number variations in helicobacter
pylori negative or positive gastric cancer samples. Data
presented are ordered by chromosomal map position of the clones.
Lower green bars represent losses or deletions, and the upper red
bars represent gains or amplifications. (A) Helicobacter pylori
negative. (B) Helicobacter pylori positive.
(PDF)
Figure S8 DNA copy number variations in EB virus
negative or positive gastric cancer samples. Data
presented are ordered by chromosomal map position of the
clones. Lower green bars represent losses or deletions, and the
upper red bars represent gains or amplifications. (A) EB virus
negative. (B) EB virus positive.
(PDF)
Figure S9 Correlation between DNA copy number
variations and global gene expression patterns. Each
chromosomal arm was divided into equal number of parts or bins of
size 20 Mb and then average pairwise Pearson correlation between
gene expression and copy number was calculated for all pairs of
binned regions. (A) Box plots of correlation between pairs along the
diagonal (cDNA clones with surrounding BAC clones) and pairs off
diagonal (cDNA clones with unrelated BAC clones). (B) Heatmap of
the average correlation between gene expression and copy number.
(PDF)
Figure S10 Correlations between the clustering pattern
and clinical features of gastric tumors. (A) Hierarchical
clustering of the patterns of variation in expression of genes in 62
gastric tumors. Each row represents a separate cDNA clone on the
microarray and each column represents the expression pattern in a
separate tumor sample. The ratio of abundance of transcripts of
each gene to its mean abundance across all tissue samples is
depicted according to the color scale shown at the bottom. Gray
indicates missing or excluded data. The dendrogram at the top of
the figure represents the hierarchical clustering of the tumors
based on similarity in their pattern of expression of these genes. (B)
Clinical features of the 62 gastric tumors.
(PDF)
Figure S11 Top biological functions of candidate genes
identified by the ingenuity pathway analysis.
(PDF)
Figure S12 Compared ERBB2 expression values with
the corresponding DNA copy number changes in 62
gastric cancer samples.
(PDF)
Table S1 Clinical parameters of 64 gastric cancer
samples.
(XLS)
Table S2 The raw data of array-based CGH.
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Table S3 DNA copy number variations in gastric cancer
samples with different clinical parameters.
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Table S4 Loci exhibiting high-level amplification or
possible homozygous deletion.
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Table S5 Genes show statistical significant correlation
between expression values and DNA copy number
variations.
(XLS)
Table S6 Candidate oncogenes and tumor suppressor
genes identified by correlating expression arrays with
aCGH data.
(PDF)
DNA CNVs and Gene Expression Analysis in GCs
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e29824Table S7 Summary of analysis (IPA).
(PDF)
Table S8 The raw data of gene expression array.
(XLS)
Acknowledgments
Somkid (Jude) Dachrut performed the array-based CGH experiments for
this study while he was a graduate student at Khon Kaen University,
Thailand, and visiting student to UCSF, USA. He passed away from an
accident on July 20, 2009 at the age of 29. This paper, therefore, is
dedicated to his memory. The authors are grateful for the support of Ritu
Roy of UCSF Cancer Center Biostatistics and Computational Biology
Core for helping with the expression/aCGH correlation analysis, as well as
Jason Au for the helpful comments for the manuscript.
Author Contributions
Conceived and designed the experiments: XC SYL JFJ. Performed the
experiments: SD HC. Analyzed the data: BF. Contributed reagents/
materials/analysis tools: STY KMC SL LHZ. Wrote the paper: BF XC
SYL JFJ.
References
1. Junnila S, Kokkola A, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O
(2010) Genome-wide gene copy number and expression analysis of primary
gastric tumors and gastric cancer cell lines. BMC Cancer 10: 73.
2. Lauren P (1965) The Two Histological Main Types of Gastric Carcinoma:
Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-
Clinical Classification. Acta Pathol Microbiol Scand 64: 31–49.
3. Mlkvy P (2010) Multimodal therapy of gastric cancer. Dig Dis 28: 615–618.
4. Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome
aberrations in solid tumors. Nat Genet 34: 369–376.
5. Kallioniemi A (2008) CGH microarrays and cancer. Curr Opin Biotechnol 19:
36–40.
6. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Siccama I, et al. (2003)
Genomic profiling of gastric cancer predicts lymph node status and survival.
Oncogene 22: 1872–1879.
7. Gorringe KL, Boussioutas A, Bowtell DD (2005) Novel regions of
chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer
identified by array comparative genomic hybridization. Genes Chromosomes
Cancer 42: 247–259.
8. Snijders AM, Fridlyand J, Mans DA, Segraves R, Jain AN, et al. (2003) Shaping
of tumor and drug-resistant genomes by instability and selection. Oncogene 22:
4370–4379.
9. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, et al. (2002) Global
gene expression analysis of gastric cancer by oligonucleotide microarrays.
Cancer Res 62: 233–240.
10. Ji J, Chen X, Leung SY, Chi JT, Chu KM, et al. (2002) Comprehensive analysis
of the gene expression profiles in human gastric cancer cell lines. Oncogene 21:
6549–6556.
11. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, et al. (2003) Variation in gene
expression patterns in human gastric cancers. Mol Biol Cell 14: 3208–3215.
12. Yuen ST, Chung LP, Leung SY, Luk IS, Chan SY, et al. (1994) In situ detection
of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg
Pathol 18: 1158–1163.
13. Japanese Gastric Cancer A (1998) Japanese Classification of Gastric Carcinoma
- 2nd English Edition. Gastric Cancer 1: 10–24.
14. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, et al. (2002)
Fully automatic quantification of microarray image data. Genome Res 12:
325–332.
15. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:
5116–5121.
16. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, et al. (2007) Gene expression
patterns of human colon tops and basal crypts and BMP antagonists as intestinal
stem cell niche factors. Proc Natl Acad Sci U S A 104: 15418–15423.
17. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a
Practical and Powerful Approach to Multiple Testing. Journal of the Royal
Statistical Society Series B-Methodological 57: 289–300.
18. Lee SA, Ho C, Roy R, Kosinski C, Patil MA, et al. (2008) Integration of
genomic analysis and in vivo transfection to identify sprouty 2 as a candidate
tumor suppressor in liver cancer. Hepatology 47: 1200–1210.
19. Andre F, Job B, Dessen P, Tordai A, Michiels S, et al. (2009) Molecular
characterization of breast cancer with high-resolution oligonucleotide compar-
ative genomic hybridization array. Clin Cancer Res 15: 441–451.
2 0 .N o g u c h iT ,W i r t zH C ,M i c h a e l i sS ,G a b b e r tH E ,M u e l l e rW( 2 0 0 1 )
Chromosomal imbalances in gastric cancer. Correlation with histologic subtypes
and tumor progression. Am J Clin Pathol 115: 828–834.
21. Tsukamoto Y, Uchida T, Karnan S, Noguchi T, Nguyen LT, et al. (2008)
Genome-wide analysis of DNA copy number alterations and gene expression in
gastric cancer. J Pathol 216: 471–482.
22. Hodgson JG, Chin K, Collins C, Gray JW (2003) Genome amplification of
chromosome 20 in breast cancer. Breast Cancer Res Treat 78: 337–345.
23. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, et al. (2002)
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic
cancer. Genes Chromosomes Cancer 35: 353–358.
24. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, et al. (2000)
Amplification and over-expression of the AIB1 nuclear receptor co-activator
gene in primary gastric cancers. Int J Cancer 89: 217–223.
25. van Dekken H, Vissers K, Tilanus HW, Kuo WL, Tanke HJ, et al. (2006)
Genomic array and expression analysis of frequent high-level amplifications in
adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet
166: 157–162.
26. Nupponen NN, Isola J, Visakorpi T (2000) Mapping the amplification of
EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer 28:
203–210.
27. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human
neoplastic disease. Oncogene 18: 3004–3016.
28. Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by
Myc proteins. Nat Rev Mol Cell Biol 6: 635–645.
29. Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol
Pathol 10: 139–152.
30. Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F (2006) HER 2/
neu protein expression in colorectal cancer. BMC Cancer 6: 123.
31. Myllykangas S, Junnila S, Kokkola A, Autio R, Scheinin I, et al. (2008)
Integrated gene copy number and expression microarray analysis of gastric
cancer highlights potential target genes. Int J Cancer 123: 817–825.
32. Heidenblad M, Lindgren D, Veltman JA, Jonson T, Mahlamaki EH,
et al. (2005) Microarray analyses reveal strong influence of DNA copy
number alterations on the transcriptional patterns in pancreatic cancer:
implications for the interpretation of genomic amplifications. Oncogene 24:
1794–1801.
33. Thollet A, Vendrell JA, Payen L, Ghayad SE, Ben Larbi S, et al. (2010) ZNF217
confers resistance to the pro-apoptotic signals of paclitaxel and aberrant
expression of Aurora-A in breast cancer cells. Mol Cancer 9: 291.
3 4 . C h uD ,Z h a n gZ ,Z h o uY ,W a n gW ,L iY ,e ta l .( 2 0 1 1 )N o t c h 1a n dN o t c h 2
have opposite prognostic e f f e c t so np a t i e n t sw i t hc o l o r e c t a lc a n c e r .A n n
Oncol.
35. Allen TD, Rodriguez EM, Jones KD, Bishop JM (2011) Activated Notch1
induces lung adenomas in mice and cooperates with Myc in the generation of
lung adenocarcinoma. Cancer Res 71: 6010–6018.
36. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, et al. (2009) The activated
Notch1 signal pathway is associated with gastric cancer progression through
cyclooxygenase-2. Cancer Res 69: 5039–5048.
37. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM (1991) Novel zinc
finger gene implicated as myc collaborator by retrovirally accelerated
lymphomagenesis in E mu-myc transgenic mice. Cell 65: 753–763.
38. Wang Q, Li WL, You P, Su J, Zhu MH, et al. (2009) Oncoprotein BMI-1
induces the malignant transformation of HaCaT cells. J Cell Biochem 106:
16–24.
39. Lee K, Adhikary G, Balasubramanian S, Gopalakrishnan R, McCormick T,
et al. (2008) Expression of Bmi-1 in epidermis enhances cell survival by
altering cell cycle regulatory protein expression and inhibiting apoptosis.
J Invest Dermatol 128: 9–17.
40. Song W, Tao K, Li H, Jin C, Song Z, et al. (2010) Bmi-1 is related to
proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 101:
1754–1760.
41. Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, et al. (2010) BMI1 and Mel-18
oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer
9: 40.
42. Potla L, Boghaert ER, Armellino D, Frost P, Damle NK (2002) Reduced
expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29
colon carcinoma cells. Cancer Lett 175: 187–195.
43. Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, et al. (2005) EPHA2/
EFNA1 expression in human gastric cancer. Cancer Sci 96: 42–47.
44. An CH, Park SW, Yoo NJ, Lee SH (2011) Mutational analysis of NCOA2 gene
in prostate cancer and other common cancers. APMIS 119: 317–318.
45. Miyoshi M, Okajima T, Matsuda T, Fukuda MN, Nadano D (2007) Bystin in
human cancer cells: intracellular localization and function in ribosome
biogenesis. Biochem J 404: 373–381.
46. Wang H, Xiao W, Zhou Q, Chen Y, Yang S, et al. (2009) Bystin-like protein is
upregulated in hepatocellular carcinoma and required for nucleologenesis in
cancer cell proliferation. Cell Res 19: 1150–1164.
47. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, et al. (2005)
Suppression of RAD21 gene expression decreases cell growth and enhances
DNA CNVs and Gene Expression Analysis in GCs
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e29824cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol
Cancer Ther 4: 361–368.
48. Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF (2008) Development
of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent.
Mol Cell Biol 28: 1489–1502.
49. White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, et al. (2010) IQGAP1
and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC
Gastroenterol 10: 125.
50. Jin SH, Akiyama Y, Fukamachi H, Yanagihara K, Akashi T, et al. (2008)
IQGAP2 inactivation through aberrant promoter methylation and promotion of
invasion in gastric cancer cells. Int J Cancer 122: 1040–1046.
DNA CNVs and Gene Expression Analysis in GCs
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e29824